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Abstract
Objective: Evaluate the frequency of failure of eight treatments for non-complicated malaria
caused by Plasmodium falciparum in patients from Turbo (Urabá region), El Bagre and Zaragoza
(Bajo Cauca region), applying the 1998 protocol of the World Health Organization (WHO).
Monotherapies using chloroquine (CQ), amodiaquine (AQ), mefloquine (MQ) and sulphadoxine-
pyrimethamine (SP), and combinations using chloroquine-sulphadoxine-pyrimethamine (CQ-SP),
amodiaquine-sulphadoxine-pyrimethamine (AQ-SP), mefloquine-sulphadoxine-pyrimethamine
(MQ-SP) and artesunate-sulphadoxine-pyrimethamine (AS-SP), were examined.
Methodology: A balanced experimental design with eight groups. Samples were selected based
on statistical and epidemiological criteria. Patients were followed for 21 to 28 days, including seven
or eight parasitological and clinical evaluations, with an active search for defaulting patients. A non-
blinded evaluation of the antimalarial treatment response (early failure, late failure, adequate
response) was performed.
Results: Initially, the loss of patients to follow-up was higher than 40%, but the immediate active
search for the cases and the monetary help for transportation expenses of patients, reduced the
loss to 6%. The treatment failure was: CQ 82%, AQ 30%, MQ 4%, SP 24%, CQ-SP 17%, AQ-SP 2%,
MQ-S-P 0%, AS-SP 3%.
Conclusion: The characteristics of an optimal epidemiological monitoring system of antimalarial
treatment response in Colombia are discussed. It is proposed to focus this on early failure
detection, by applying a screening test every two to three years, based on a seven to 14-day follow-
up. Clinical and parasitological assessment would be carried out by a general physician and a field
microscopist from the local hospital, with active measures to search for defaulter patients at follow-
up.
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Background
After the use of any antimicrobial, treatment failure or
resistance occurs in a percentage of cases, due to the vari-
ants or genetic mutants. In Plasmodium, mutations appear
with a frequency of 9.5-71.2 × 10-10 mutations/site/year in
coding regions [1] and with a frequency of 1.5910 × 10-4
mutations/site/year in microsatellites [2].
The in vitro evaluation of resistance of Plasmodium to an
antimalarial drug consists of assessing growth inhibition
when exposed to different concentrations of the drug, and
several methods have been described [3-6]. The in vivo
evaluation, or therapeutic efficacy test (TET), measures the
clinical and parasitological response of malaria patients to
a specific antimalarial treatment. The clinical response is
indicated by the clearance of symptoms and signs, and the
parasitological response by the clearance of blood para-
sites, after oral administration of recommended doses of
one or several drugs, under supervision of the sanitary
staff, and with a follow-up during a determined period
(usually, 7 to 28 days). The TET evaluation protocol,
approved by the World Heath Organization (WHO) in
1998 [7], has been used in many South-American studies.
In this protocol, TET has been classified into three catego-
ries: early treatment failure, late treatment failure and ade-
quate response. This treatment failure refers exclusively to
inability to be cured of malaria, not to the inability to pre-
vent the disease when the drug has been used in a prophy-
lactic fashion. Treatment failure has been described in two
out of the four species of Plasmodium, which affect
humans: Plasmodium vivax and, especially, Plasmodium fal-
ciparum; the latter has shown resistance to many antima-
larial drugs [8].
In Colombia, between 1961 and 2003 (Table 1), the non-
weighed mean of treatment failure in falciparum malaria
was 66% for CQ (13 reports), 22% for AQ (9 reports) and
15% for SP (14 reports). In recent publications, the failure
of the malaria control programme in Colombia has been
described and the causes analysed [9-11]. The geographic,
environmental, socio-demographic, economic character-
istics and general malaria morbi-mortality, in Antioquia,
Table 1: Frequency (%) of failure in vivo in antimalarial treatment; Colombia, 1961–2003 (1)
Place, Drug (2) CQ AQ SP Reference
Colombia 82,0 Walker 1968 [38]
Colombia (4) 16,4 28,3 34,7 Blair 1986 [39]
Colombia (5) 24,0 (quoted in Ravreda 2003) [40]
Colombia (5) 25,0 (quoted in Ravreda 2003) [40]
Colombia in vitro 96,0 3,3 Espinal 1985 [41]
Antioquia (state) 34,0 (Restrepo quoted in Ravreda 2003) [40]
El Bagre (Ant ioquia) 82,0 38,0 10,0 Flórez 1988 [42]
El Bagre (Ant ioquia) 71,0 12,0 15,0 López 1999 [27]
Turbo (Ant ioquia) 97,0 7,0 13,0 Blair 1999, 2001 [28, 29]
Zaragoza (Ant ioquia) 67,0 3,0 9,0 Blair 1999, 2002 [28, 30]
Chocó (state) 52,0 Comer 1968 [43]
Quibdó, (Chocó) 44,0 Osorio 1999 [44]
Quibdó, (Chocó) 6,0 Osorio 1999 [44]
Tadó, (Chocó) 27,0 16,0 (González 2002 quoted in Ravreda 2003) [40]
Cali (Valle) 78,0 Castillo 2002 [45]
Buenaventura (Valle) 3,0 Méndez 2002 [46]
Tumaco (Nariño) 70,0 54,0 Flórez 1988 [42]
Tumaco (Nariño) 40,0 18,0 0,0 Flórez 1988 [42]
Tumaco (Nariño) 50,0 15,3 González 2003 [31]
El Charco (Nariño) 0,0 0,0 González 2003 [31]
Orinoquía y Amazonía (3) Espinal 1985 [41]
Average 66,3 21,9 14,6
Mean 70,0 19,9 14,6
(1) Response evaluated in patients (in vivo), except when the contrary has been indicated (in vitro). Duration: approximately from 1961–2003. Blank 
cells: It was not possible to find information.
(2) AQ amodiaquine, CQ chloroquine, SP sulphadoxine-pyrimethamine, CL clindamicina, MQ mefloquine.
(3) Espinal's report 1985 [41]: it does not mention the amount of failure to SP; it only refers to 3 cases in Orinoquía and 9 in Amazonía.
(4) AQ-CL: Blair 1986 [39] reports one study with 3,8% of failure.
(5) MQ-SP: failure of 0% in 1982 and in 1985; also failure of 0% in Botero et al. 1985 [47]. For MQ: 8.3% of failure in Amazonía.
(6) AQ-SP: González report [31], 11.0% of failure in this place.Malaria Journal 2006, 5:14 http://www.malariajournal.com/content/5/1/14
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Urabá and Bajo Cauca regions as well as in El Bagre and
Turbo municipalities have been detailed by others articles
[10,12-15]. Demographic and epidemiological changes
ocuring in Colombia during the XXth century have been
reviewed and detailed elsewhere [16]. These reports con-
stitute an integral reference framework to interpret the
antimalarial treatment failure and resistance and to out-
line policies and programmemes to reduce their effects.
On this background, this report: a) collects and summa-
rizes the available information about treatment failure in
Colombia; b) presents the results of the evaluation of TET
for various treatment schedules, between 2000 and 2004,
in the municipalities of Turbo (Urabá region), El Bagre
and Zaragoza (Bajo Cauca region), in the north-west and
north-east of the state of Antioquia, Colombia; c) collects
and summarizes information about use of the combina-
tion AQ-SP for the treatment of non-complicated falci-
parum malaria; and d) discusses the creation of an
epidemiological surveillance system of antimalarial treat-
ment failure as part of the malaria programmeme operat-
ing in the country.
Materials and methods
Design of studies
The TET with eight schemes was assessed in a sequential
way, between 2000 and 2004. All throughout the study
period at least two simultaneous groups were being stud-
ied. Patients were randomly assigned a specific treatment
as they arrived; this was guaranteed by a blind lottery
(tombola). The group of studies constitute an experimen-
tal design (randomized clinical trial or clinical controlled
study) [17] with eight equal groups, where the "exposi-
tion factor" (explicative variable) has been constituted by
each treatment, and the "effect" corresponds to the thera-
peutic response.
Site of study
Urabá and Bajo Cauca, two regions of the Antioquia state,
generate 90% of malaria cases of this state. Urabá is
located on Urabá Gulf in the Caribbean sea, near the bor-
ders with Panama; the territory has mostly a warm cli-
mate. Antioquian Bajo Cauca is located north of the state
and has mostly a humid-very humid warm climate [18-
20].
The Urabá region extends over 11,671 km2, while the Bajo
Cauca region extends over 8,498 km2. In June 2002,
Urabá had 463,496 inhabitants and Bajo Cauca 219,951.
The Urabá population density was 36,4 inhabitants/km2
in 1998 and 39,7 in 2002; in Bajo Cauca it was 21.5 in
1993 and 25.8 in 2002 [18-20]. In these two regions, the
whole population is exposed to risk of malaria. Most of
the inhabitants of these two regions are "mestizos" (cre-
oles). In Urabá, there are few indian comunities: Kunas
(Tule), Emberas (Katíos) and Zenúes [19]. From 1995 to
2000, the displaced population was 25,000 in Urabá and
5,000 in Bajo Cauca [18] but this was notorious between
2001 and 2005 [21].
In Turbo, 60% of the population lives in rural areas (vil-
lages or small towns), while in El Bagre only 38% lives in
the rural area. The age structure of the two populations is
similar [22]. In 2002, 8.38% of the Antioquia population
lived in Urabá and 3.98% in Bajo Cauca. On the other
hand, Turbo had 25.62% of Urabá population while El
Bagre had 27.20% of Bajo Cauca population.
Outwash mining is the principal economic activity of Bajo
Cauca, followed by cattle farming and, to a lesser degree,
rice and sorghum cultivation [20]. In Urabá, the banana
growing industry is the main activity, mostly concentrated
in the central zone, followed by cattle farming in the
northern part and timber exploitation from natural forests
in the southern zone. There has been substantial migra-
tion of populations over the past 20 years, for economic
and socio-political reasons. These migrations have con-
tributed to the malaria problem, spreading P. falciparum
resistant to chloroquine and other drugs, as was the case
on the borders of Thailand with Cambodia and Myanmar
[8].
The mean Annual Parasite Index (API) was 39 cases per
1,000 inhabitants in Turbo (1995–2000), 134 in El Bagre
(1995–2000) and 33.5 in Zaragoza (1998–2000). For the
period 2001–2003, the API was 19.5 in Turbo, 37.5 in El
Bagre and 34.5 in Zaragoza (DSSA data). These data, with
an API above 10/1,000, confirm the high-risk for malaria
transmission in these regions.
Sample design
The calculated size sample was 42 for each of the eight
treatment schedules, and for each region selected (Turbo,
El Bagre and Zaragoza). The sample size was increased to
50 patients (a 20% increase) to compensate for losses dur-
ing the follow-up period. This sample size was based on
the 1998 WHO protocol [7]. The confidence level was
95% (alpha error = 0.05) and the power of the statistical
test was 80% (beta error = 0.20). In 1998, the number of
patients with falciparum malaria was 2,200 (total for the
three municipalities) [23]. The expected proportion of
occurrence of the treatment failure event varies for each
treatment and this was, therefore, estimated to 50% for all
treatments, in order to obtain a larger sample. The sam-
pling error was fixed to 15%.
Reference population
The reference population was composed of patients with
a history of fever for two to three days, with symptoms
compatible with malaria, and a unique infection with P.Malaria Journal 2006, 5:14 http://www.malariajournal.com/content/5/1/14
Page 4 of 9
(page number not for citation purposes)
falciparum  confirmed by thick smear. These patients
attended the malaria diagnosis clinic at their local hospi-
tal. Males and non-pregnant females (confirmed by a fast
pregnancy test), above one year of age, living in the rural
or urban zone of their municipality, where they normally
reside, were included in the study.
Inclusion criteria
Inclusion criteria, besides the features described in "Refer-
ence Population" were: a) to have non-complicated
malaria (according to a medical evaluation and according
to asexual parasitaemia); b) to harbor between 250 and
50,000 asexual parasites/µL; c) exclusion of concomitant
disease, after a clinical interview and examination carried
out by the research team; d) voluntary participation in the
study; e) commitment to attend the follow-up examina-
tions.
Exclusion criteria
Criteria for exclusion of the study were: a) to evidence, at
any moment, severe malaria or any other disease; b)
appearance of serious adverse effects due to antimalarial
drugs, to other medicines, or to other causes; c) failure to
attend any of the first three follow-up examinations (days
1, 2, 3). The evidence of treatment failure to antimalarial
therapy resulted in withdrawal from the study and recom-
mendation of a rescue treatment, formulated according to
the Colombian Health Ministry guidelines for malaria
treatment [24].
Malaria diagnosis, clinical and parasitological evaluation
Malaria diagnosis was carried out with thick smear accord-
ing to WHO procedure [25] and routinely used in Colom-
bia. The thick smear and the thin smear were Field- and
Giemsa-stained, respectively. The thick smear was exam-
ined by microscopy (100×) and the search for parasites
was carried out in 200 consecutive microscopic fields. Par-
asitaemia was calculated on the basis of 200 leucocytes
and a constant of 8,000 leucocytes/µL, and was expressed
in parasites/µL. A thick smear was diagnosed as negative
when no asexual forms were observed in 200 fields. Para-
sitaemia was reported as asexual parasites/mm3, accord-
ing to 1998 WHO protocol [7].
Each patient, upon admission to the study and at each fol-
low-up, was given: a) a medical evaluation to diagnose the
presence of malaria; b) a parasitological evaluation (thick
smear, thin smear and parasite count). Special emphasis
put on finding, identifying, classifying and defining the
origin of adverse effects, which appeared during the 21 to
28 days of follow-up. This search for adverse effects was
based on clinical assessment (symptoms, signs), rather
than laboratory evaluation. The field team was composed,
in each municipality, of a general physician and a clinical
laboratory technician, interacting with the local malaria
team, a microscopist and a health assistant. An active
search for defaulting patients was carried out when
needed in order to re-integrate them to the study.
Treatment
The drugs were taken with water, administered in the
doses established by the Colombian Ministry of Health
[24] (Table 2). Each treatment was given under supervi-
sion by the researchers and the patient was observed dur-
ing the first half hour. In case of vomiting, the complete
dose was supplied again, and the 30-minute observation
was repeated. If the patient vomited again, he was
excluded and referred to the local hospital. On the last day
of follow-up, all patients were administered primaquine,
as gametocytocide, in a single dose (0.75 mg/kg; lot
C091200).
Classification of the treatment response
The follow-up period lasted 28 days in the three groups
(AQ, MQ-SP, AS-SP) and 21 days in the five other groups
(CQ, MQ, SP, CQ-SP, AQ-SP). TET was classified based on
the 1998 WHO protocol [7] with minor changes:
1. Early treatment failure, defined as the presence of any
of the following:
a) Development of danger signs or severe malaria on Day
1 Day 2 or Day 3
b) Parasitaemia on day 2 higher than day 0;
c) Parasitaemia on day 3 ≥ 25% of count on day 0.
2. Late treatment failure, defined as the presence of any of
the following:
a) Danger signs or severe malaria in the presence of para-
sitaemia (same species of day 0) after day 3;
b) Non-programmemed return of the patient between
days 4 to 21 (CQ, SP, CQ+SP) or 28 (for other), due to a
clinical deterioration in the presence of parasitaemia
(same species of day 0).
c) Parasites (same species of day 0) on days 7, 14, 21, or
28.
3. Adequate clinical-parasitological response: if the
patient did not present either early or late failures.
Data processing and statistical analysis
The EpiInfo 6.04 programmeme was used to make ques-
tionnaires and data bases and also to analyse information
(Centers for Disease Control and Prevention, USA; World
Health Organization, Geneva, Switzerland. EpiInfo 6.04).Malaria Journal 2006, 5:14 http://www.malariajournal.com/content/5/1/14
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SPSS 10.0 was also used for data analysis and graph con-
struction.
Associations among groups or independent variables
(such as treatment schedules, type of treatment response)
were measured with square chi test (χ2); the means were
compared with Wilcoxon or Kruskal-Wallis (K-W) tests. A
significance level of 5% (α = 0.05) was always established.
The following abbreviations and expressions were used: n
= number of patients, X = mean or average or arithmetic
mean, Me = median, SD = Standard deviation, SE = Stand-
ard error, P25 = percentile 25, P75 = percentile 75, IC95%
= confidence interval of 95% for a determined value, such
as the mean; LL and HL are lower or high limits of IC95%,
p = probability.
Ethical approval
Written informed consent from each patient or guardian
of an underage child, was obtained. Each project was
approved by the Ethics Committee and by the Center of
Medical Investigations (CIM) of Universidad de Antio-
quia.
Results
Of the 520 patients included in the study, 47% were
recruited in Turbo (Urabá zone) and 53% in The Bajo
Cauca zone (El Bagre 37% and Zaragoza 16%). Data were
analysed independently from the residence place of the
patient since important differences were not found when
this variable was considered.
The patients exhibited the following characteristics:
a) 61% were living in the rural zone
b) 69% were men
c) 29% were under 15 years of age (3% <5, 11% 5–9 years,
15% 10–14 years, 1% were older than 64 years, and the
remaining 70% corresponded to patients from 15 to 64
years old (34% 15–24, 27% 25–44 and 9% 45–64 years).
TET could be measured in 93.7% of the patients (487 out
of 520 patients). The reason for not evaluating TET in 33
patients was the impossibility of finding them (90%: 30/
33) or voluntary withdrawal from the investigation (10%:
3/33). Failure to attend increased further into the follow-
up time. Such defaulting was statistically different among
treatments, and the four monotherapies had less default-
ing overall (4%) than the four treatment combinations
(8%). This percentage of defaulting per treatment varied
from major to minor: a) in monotherapies: it was 9% with
MQ, 3% with AQ, none with CQ and SP; b) in combina-
tions: it was 12% with MQ-SP, 10% with AQ-SP and AS-
SP, none with CQ-SP. Defaulting was higher (9.3%) in El
Bagre-Zaragoza, which largely depends for communica-
tion on the Nechí River, than in Turbo (5.7%), in which
basic transport is by land. The group of 33 non-attending
patients did not differ from the non-defaulters (n = 487)
in relation to the residence zone (urban, rural), sex, eth-
nicity, age, days of evolution of the current disease and
initial parasitaemia.
The mean of asexual parasitaemia in 487 patients before
treatment administration was 7,700 parasites/µL, the
median was 4,480, the 25 percentile was 2,000; the 75
Table 2: Antimalarial drugs administered in eight studies of treatment response. Antioquia (Colombia), 2000–2004 (1)
Treatment Total Dose Rescue Treatment
Chloroquine 25 mg/kg: 10 mg/kg day 1; 7.5 mg/kg days 1 and 2 Quinine sulphate – CL
Amodiaquine 25 mg/kg: 10 mg/kg day 1; 7.5 mg/kg days 1 and 2 Mefloquine – SP
Mefloquine 15 mg/kg only one dose on the day 1 Quinine sulphate – SP
Sulphadoxine-pyrimethamine (SP) 25 mg/kg S + 1.25 mg/kg P only one dose day 1 Quinine sulphate – CL
Chloroquine-SP 25 mg/kg: 10 mg/kg day 1; 7.5 mg/kg days 1 and 2 Quinine sulphate – CL
25 mg/kg S + 1.25 mg/kg P only one dose day 1
Amodiaquine-SP 25 mg/kg: 10 mg/kg day 1; 7.5 mg/kg days 1 and 2 Mefloquine
25 mg/kg S + 1.25 mg/kg P only one dose day 1
Mefloquine-SP 15 mg/kg only one dose day 1 Amodiaquine – SP
25 mg/kg S + 1.25 mg/kg P only one dose day 1
Artesunate-SP 12 mg/kg: 4 mg/kg días 0, 1 y 2 Amodiaquine – SP
25 mg/kg S + 1.25 mg/kg P only one dose day 1
(1) S sulphadoxine, P pyrimethamine, SP sulphadoxine-pyrimethamine, CL clindamicine.
AQ year 2002 lot 00L22/0439E tab 150 mg Alkem Laboratory; year 2003 lot 3001-ET, Alkem Laboratory.
MQ year 2002 lot 51009 tab 250 mg, Mepha Laboratory; year 2003: lot 350866, Mepha Laboratory.
SP years 2000–2001 lot Sul 50600606; year 2002 lot 09017 RE tab500/25 mg, VAP Laboratory; year 2003–2004: lot RJ0002, Roche Laboratory.
AS lot 351237 Mepha Laboratory.
CQ lot C141100.
QN lot 98C12.
CL lot 000101Malaria Journal 2006, 5:14 http://www.malariajournal.com/content/5/1/14
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percentile was 10,130 and the standard deviation was
8,472 parasites/µL. A 26% of patients had as many as
2,000 parasites/µL, 45% as many as 4,000, 50% up to
5,000, 75% up to 10,000 and only 8% over 20,000 para-
sites/µL.
The mean asexual parasitaemia before treatment adminis-
tration was not statistically equal among the treatments; it
varied between 8,954 (MQ) and 5,203 parasites/µL (CQ-
SP) (p < 0.05); between MQ and SP (5,663 parasites/µL)
there was a statistically significant difference. Gameto-
cytes were found in 17% of patients before treatment, in
23% on day 1, 33% on day 2, 43% on day 3, 65% on day
7, 64% on day 14, 51% on day 21, and 15% on day 28.
Before the treatment, the mean number of gametocytes
ranged from 22 (AS-SP) to 140 gametocytes/µL (AQ-SP),
with a general mean of 78 and a standard deviation of 421
gametocytes/µL (minimum 0 and maximum 7,600).
Monotherapy with CQ showed 82% failure, with AQ it
showed 30%, with MQ 4%, and with SP 24%, while the
combinations of SP with other drugs showed the follow-
ing failure rates: CQ-SP 17%, AQ-SP 2%, MQ-SP 0% and
AS-SP 3% (Table 4). There were 62 failures (12,7%) in
487 patients in whom the final effect could be measured.
Early failure contributed with 42% of the total failure (26/
62) and the late failure accounted for 58% (36/62) of it.
Considering defaulting patients as failures the percentage
of failure reached 18% (62 observed failures + 30 sup-
posed failures/520). The frequency of early and late fail-
ures changes from one treatment to another: a) with
monotherapies, early and late failures were equal to the
those with CQ, early failures were predominant with AQ
(ratio 1:4), and the late ones were the majority with SP
(2:1); b) with the CQ-SP combination, the late failures
widely prevailed (9:1). With the rescue treatment, which
varied according to the primary treatment, all treatment
responses were successful; which meant no failure of two
treatments was observed.
Treatment failure was not associated with initial asexual
parasitaemia (pre-treatment), although there were impor-
tant differences as follows: those who successfully
responded and those who had early failure had 7,760 and
7,951 parasites/µL, respectively, while those who had late
failure showed 6,731 parasites/µL; despite that, the differ-
ences were not statistically significant. Neither was there
any relation of TET with initial gametocytaemia. Thus,
although initial asexual parasitaemia was not equal in all
eight treatments, this fact did not have any effect in the
TET.
It should be pointed out that there was no significant
association of the variable TET with any one of these expli-
cative variables: municipality, zone, sex, age group, ethnic
group, malaria antecedents, and hospitalization or trans-
fusion antecedents.
Discussion
Antimalarial schemes administered (dose, scheme, appli-
cation time) corresponded to those used for many years in
Colombia and recommended by other authors [8,26].
Direct surveillance of patients by the researchers during
drug intake assured that the drugs were taken, and ruled
out losses due to vomiting or diarrhea.
The protocol used for measuring TET was identical in
most studies, with exception of the studies of 2000–2001,
when CQ, SP and CQ-SP were evaluated over 21 days; in
those undertaken between 2001 and 2004, the follow-up
lasted 28 days.
The number of patients in whom TET could not be meas-
ured (lost patients) was low (6% in the eight studies) and
was not affected by the minimum sampling size. The strat-
egy used to avoid defaulting consisted of monetary sup-
port (of up to 5,000 Colombian pesos, i.e. less than
US$2) to cover transportation costs, as well as the Imme-
diate Active Search (IAS) for any patient who missed a fol-
low-up examination. In fact, defaulting rate has been
higher than 40%, but was reduced to 6% through the
application of that strategy. IAS was performed by the
physician or clinical laboratory technician, accompanied
by the health assistant, using motorcycles supplied by the
local hospital. Even in the worst case scenario, i.e. if all
patients in whom TET was could not be measured are con-
sidered as failures, the percentage of treatment failure for
each treatment schedule was under 14%, except in the
case of AQ, which had net failure (excluding defaulters) of
30%, and gross failure of 33% (when counting defaulters
as failures).
From the evaluated schizonticide monotherapies (CQ,
AQ, MQ, SP), only CQ has been used in this way in
Colombia, although associated to primaquine as gameto-
cide (45 mg in a single dose). CQ had become useless in
1998 (according to López et al. [27] and Blair et al [28-
30]), due to recorded failures between 71% and 67% now
reaching 82%. The national average of CQ failure from
1961–2003 is 66% (Table 1), which indicates that it
should no longer be used anywhere in the country. The
CQ-SP combination (failure 17%) seems to remains use-
ful, but efficacy should be evaluated in other areas (e.g.
Orinoquia, Amazonia, Catatumbo).
The accelerated growth of failure presented by the mono-
therapy AQ is serious because it increased from 7% in
1998 in El Bagre [27], Zaragoza [28,30] and Turbo [28,29]
to 30% in 2004, which excludes the drug for mono-
therapy, according to the 25% threshold proposed byMalaria Journal 2006, 5:14 http://www.malariajournal.com/content/5/1/14
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WHO [7]. The national average of AQ failure is 22%, but
there are recent data (2002–2003) coming from Tadó
(Chocó) indicating a failure rate of 27% (Table 1) and
from Tumaco (Nariño) which reports 50%, although
there was no failure in El Charco, in the same state [31].
Failure of the monotherapy with SP also increased
strongly, going from 12% in 1998 [27-30] to 24% current.
The MQ-SP combination showed a zero failure rate, but
AS-SP showed a failure of 3%, although never officially
used in Colombia.
The AQ-SP combination is highly efficient (98%). The rel-
atively scantly use of the AQ was a result of the adverse
reactions which had been observed when AQ was used for
prophylaxis [32], a situation in which it is taken for weeks
or months, but reports on serious adverse effects of its use
as an antimalarial are practically absent [33-35]. In a dif-
ferent study carried out by us in Turbo, 57 patients treated
with AQ monotherapy were clinically and laboratory
(blood and liver tests) assessed before treatment and 10
days after it. We concluded that, at the standard dose (25
mg/kg peso) and period (3 days), as recommended for
uncomplicated falciparum malaria, AQ had no adverse
effects or toxicity (paper in preparation).
A systematic review of 2001 compared AQ-SP and CQ-SP
combinations for the treatment of non-complicated
malaria; on the basis of seven studies in 1,277 patients, it
concluded that there was no evidence of serious collateral
effects with those combinations and that they, more than
monotherapy with SP, "could make people feel better
more rapidly", and caused a better steady elimination of
blood parasites [36]. In 2005, a Cochrane review aimed at
assessing " the combination of CQ or AQ plus SP com-
pared with SP alone for first-line treatment of uncompli-
cated falciparum malaria", concluded that "the evidence
base is not strong enough to support firm conclusions.
The available evidence suggests that AQ plus SP can
achieve less treatment failure than SP, but this might
depend on existing levels of parasite resistance to the indi-
vidual drugs" [37].
According to the results obtained in this study and to the
additional information presented here, treatment with
AQ-SP should remain as the first line treatment of non-
complicated falciparum malaria in Colombia, as it is at
present [24], leaving options based on MQ and on AS for
the future, once AQ-SP has failed.
Colombia should establish an "Antimalarial Failure Epi-
demiological Surveillance System" (AFESS). The AFESS
should have, as primary objective, the early detection of
failure by means of a screening test. For this, a selected
screen test should be low cost, applicable in field condi-
tions and have a high sensitivity. Our recommendation is
to install an AFESS coupled to the antimalarial program-
meme, to measure TET during a following up period of 7
– 14 days and to install sentinel posts in strategic places of
malaria regions. In addition the AFESS, should: a) carry
out specific research projects aimed at confirmation of
therapeutic failure after a following up period of 28 days
or more, b) evaluation of P. falciparum in vitro resistance;
c) P. falciparum y P. vivax genetic analysis and d) assess-
ment of antimalarial blood concentrations in patients
studied.
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Table 3: Treatment response according to antimalarial treatment; Antioquia (Colombia), 2000–2004 (1)
Response (2) CQ AQ MQ SP CQ-SP AQ-SP MQ-SP AS-SP Total
Early Failure 8 2 1 12 1 1 0 1 26
% 4 7 . 16 . 1 1 . 11 5 . 21 . 6 1 . 1 0 . 0 1 . 7 5 . 3
Late Failure 6 8 3 7 10 1 0 1 36
% 35.3 24.2 3.3 8.9 15.6 1.1 0.0 1.7 7.4
Total Failure 14 10 4 19 11 2 0 2 62
% 82.4 30.3 4.4 24.1 17.2 2.2 0.0 3.4 12.7
A d e q u a t e 3 2 38 86 05 38 85 55 5 4 2 5
% 17.6 69.7 95.6 75.9 82.8 97.8 100.0 96.6 87.3
T o t a l 1 73 39 27 96 49 05 55 7 4 8 7
% 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
(1) The eight schemes were assessed in a sequential way, between 2000 and 2004.
(2) Failures %: Total failures (early failures + late failures)/patients with measured antimalarial treatment response; it means, non counting the lost 
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